| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-13 11:47:17 UTC |
|---|
| Update Date | 2021-09-14 15:40:14 UTC |
|---|
| HMDB ID | HMDB0041908 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Imidaprilat |
|---|
| Description | Imidaprilat, is the active metabolite of Imidapril. Imidapril is a prodrug used to treat hypertension, chronic congestive heart failure (CHF), acute myocardial infarction (AMI), and diabetic nephropathy (PMID: 17547476 ,18192036 ,12177688 , 17094051 ). Imidapril belongs to a class of long-acting, non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitors (PMID: 8851752 , 12177688 ). Imidaprilat competitively binds and inhibits the catalytic activity of ACE, which results in a reduction of peripheral resistance and a reduction in systemic blood pressure (BP) (PMID: 17547476 ). Imidaprilat is only found in individuals that have used or taken imidapril. |
|---|
| Structure | [H][C@@](C)(N[C@@]([H])(CCC1=CC=CC=C1)C(O)=O)C(=O)N1C(=O)N(C)C[C@@]1([H])C(O)=O InChI=1S/C18H23N3O6/c1-11(15(22)21-14(17(25)26)10-20(2)18(21)27)19-13(16(23)24)9-8-12-6-4-3-5-7-12/h3-7,11,13-14,19H,8-10H2,1-2H3,(H,23,24)(H,25,26)/t11-,13-,14-/m0/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| (4S)-1-Methyl-3-{(2S)-2-[N-((1S)-1-carboxy-3-phenylpropyl)amino]propionyl}-2-oxo-imidazolidine-4-carboxylic acid | ChEBI | | Imidaprilate | ChEBI | | Imidaprilatum | ChEBI | | (4S)-1-Methyl-3-{(2S)-2-[N-((1S)-1-carboxy-3-phenylpropyl)amino]propionyl}-2-oxo-imidazolidine-4-carboxylate | Generator | | Imidaprilic acid | Generator | | 6366a | HMDB | | Imidaprilat, (4S-(3(R(r*)),4R*))-isomer | HMDB | | Imidaprilat, monosodium salt, (4S-(3(r*(r*)),4R*))-isomer | HMDB | | 3-(2-(N-(1-Carboxy-3-phenylpropyl)amino)propionyl)-1-methyl-2-oxoimidazolidine-4-carboxylic acid | HMDB | | Imidaprilat hydrochloride, (4S-(3(r*(r*)),4R*)) | HMDB | | Imidaprilat hydrochloride, (4S-(3(s*(r*)),4R*))-isomer | HMDB |
|
|---|
| Chemical Formula | C18H23N3O6 |
|---|
| Average Molecular Weight | 377.3917 |
|---|
| Monoisotopic Molecular Weight | 377.158685483 |
|---|
| IUPAC Name | (4S)-3-[(2S)-2-{[(1S)-1-carboxy-3-phenylpropyl]amino}propanoyl]-1-methyl-2-oxoimidazolidine-4-carboxylic acid |
|---|
| Traditional Name | (4S)-3-[(2S)-2-{[(1S)-1-carboxy-3-phenylpropyl]amino}propanoyl]-1-methyl-2-oxoimidazolidine-4-carboxylic acid |
|---|
| CAS Registry Number | 89371-44-8 |
|---|
| SMILES | [H][C@@](C)(N[C@@]([H])(CCC1=CC=CC=C1)C(O)=O)C(=O)N1C(=O)N(C)C[C@@]1([H])C(O)=O |
|---|
| InChI Identifier | InChI=1S/C18H23N3O6/c1-11(15(22)21-14(17(25)26)10-20(2)18(21)27)19-13(16(23)24)9-8-12-6-4-3-5-7-12/h3-7,11,13-14,19H,8-10H2,1-2H3,(H,23,24)(H,25,26)/t11-,13-,14-/m0/s1 |
|---|
| InChI Key | VFAVNRVDTAPBNR-UBHSHLNASA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organic acids and derivatives |
|---|
| Class | Carboxylic acids and derivatives |
|---|
| Sub Class | Amino acids, peptides, and analogues |
|---|
| Direct Parent | Dipeptides |
|---|
| Alternative Parents | |
|---|
| Substituents | - Alpha-dipeptide
- N-acyl-l-alpha-amino acid
- Alpha-amino acid amide
- Alpha-amino acid
- Alpha-amino acid or derivatives
- L-alpha-amino acid
- N-acyl urea
- Aralkylamine
- Ureide
- Imidazolidinone
- Monocyclic benzene moiety
- Dicarboxylic acid or derivatives
- Benzenoid
- Dicarboximide
- Imidazolidine
- Urea
- Amino acid
- Amino acid or derivatives
- Carbonic acid derivative
- Carboxylic acid
- Secondary aliphatic amine
- Azacycle
- Organoheterocyclic compound
- Secondary amine
- Organic oxygen compound
- Organic nitrogen compound
- Carbonyl group
- Hydrocarbon derivative
- Organopnictogen compound
- Amine
- Organic oxide
- Organooxygen compound
- Organonitrogen compound
- Aromatic heteromonocyclic compound
|
|---|
| Molecular Framework | Aromatic heteromonocyclic compounds |
|---|
| External Descriptors | Not Available |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Not Available |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 3.21 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 11.3133 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 5.09 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 153.2 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 1571.7 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 202.1 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 128.6 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 162.6 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 92.4 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 351.2 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 415.4 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 323.5 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 844.9 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 411.9 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1367.1 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 261.7 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 264.4 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 329.2 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 175.4 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 130.2 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Imidaprilat,1TMS,isomer #1 | C[C@H](N[C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C)C(=O)N1C(=O)N(C)C[C@H]1C(=O)O | 2923.4 | Semi standard non polar | 33892256 | | Imidaprilat,1TMS,isomer #2 | C[C@H](N[C@@H](CCC1=CC=CC=C1)C(=O)O)C(=O)N1C(=O)N(C)C[C@H]1C(=O)O[Si](C)(C)C | 2945.3 | Semi standard non polar | 33892256 | | Imidaprilat,1TMS,isomer #3 | C[C@@H](C(=O)N1C(=O)N(C)C[C@H]1C(=O)O)N([C@@H](CCC1=CC=CC=C1)C(=O)O)[Si](C)(C)C | 2970.8 | Semi standard non polar | 33892256 | | Imidaprilat,2TMS,isomer #1 | C[C@H](N[C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C)C(=O)N1C(=O)N(C)C[C@H]1C(=O)O[Si](C)(C)C | 2890.6 | Semi standard non polar | 33892256 | | Imidaprilat,2TMS,isomer #2 | C[C@@H](C(=O)N1C(=O)N(C)C[C@H]1C(=O)O)N([C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C)[Si](C)(C)C | 2902.9 | Semi standard non polar | 33892256 | | Imidaprilat,2TMS,isomer #3 | C[C@@H](C(=O)N1C(=O)N(C)C[C@H]1C(=O)O[Si](C)(C)C)N([C@@H](CCC1=CC=CC=C1)C(=O)O)[Si](C)(C)C | 2907.8 | Semi standard non polar | 33892256 | | Imidaprilat,3TMS,isomer #1 | C[C@@H](C(=O)N1C(=O)N(C)C[C@H]1C(=O)O[Si](C)(C)C)N([C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C)[Si](C)(C)C | 2903.3 | Semi standard non polar | 33892256 | | Imidaprilat,3TMS,isomer #1 | C[C@@H](C(=O)N1C(=O)N(C)C[C@H]1C(=O)O[Si](C)(C)C)N([C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C)[Si](C)(C)C | 2908.8 | Standard non polar | 33892256 | | Imidaprilat,1TBDMS,isomer #1 | C[C@H](N[C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C(C)(C)C)C(=O)N1C(=O)N(C)C[C@H]1C(=O)O | 3152.0 | Semi standard non polar | 33892256 | | Imidaprilat,1TBDMS,isomer #2 | C[C@H](N[C@@H](CCC1=CC=CC=C1)C(=O)O)C(=O)N1C(=O)N(C)C[C@H]1C(=O)O[Si](C)(C)C(C)(C)C | 3174.8 | Semi standard non polar | 33892256 | | Imidaprilat,1TBDMS,isomer #3 | C[C@@H](C(=O)N1C(=O)N(C)C[C@H]1C(=O)O)N([C@@H](CCC1=CC=CC=C1)C(=O)O)[Si](C)(C)C(C)(C)C | 3187.4 | Semi standard non polar | 33892256 | | Imidaprilat,2TBDMS,isomer #1 | C[C@H](N[C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C(C)(C)C)C(=O)N1C(=O)N(C)C[C@H]1C(=O)O[Si](C)(C)C(C)(C)C | 3310.7 | Semi standard non polar | 33892256 | | Imidaprilat,2TBDMS,isomer #2 | C[C@@H](C(=O)N1C(=O)N(C)C[C@H]1C(=O)O)N([C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 3374.0 | Semi standard non polar | 33892256 | | Imidaprilat,2TBDMS,isomer #3 | C[C@@H](C(=O)N1C(=O)N(C)C[C@H]1C(=O)O[Si](C)(C)C(C)(C)C)N([C@@H](CCC1=CC=CC=C1)C(=O)O)[Si](C)(C)C(C)(C)C | 3374.5 | Semi standard non polar | 33892256 | | Imidaprilat,3TBDMS,isomer #1 | C[C@@H](C(=O)N1C(=O)N(C)C[C@H]1C(=O)O[Si](C)(C)C(C)(C)C)N([C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 3554.9 | Semi standard non polar | 33892256 | | Imidaprilat,3TBDMS,isomer #1 | C[C@@H](C(=O)N1C(=O)N(C)C[C@H]1C(=O)O[Si](C)(C)C(C)(C)C)N([C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 3492.1 | Standard non polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Imidaprilat GC-MS (Non-derivatized) - 70eV, Positive | splash10-06r6-9333000000-0342cc7c97fb89e1eed0 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Imidaprilat GC-MS (2 TMS) - 70eV, Positive | splash10-06yc-9220210000-78ec36f997b709bf0ace | 2017-10-06 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Imidaprilat GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Imidaprilat 10V, Positive-QTOF | splash10-002b-0914000000-099f0a02b987aabfaa0f | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Imidaprilat 20V, Positive-QTOF | splash10-06tb-2921000000-6f70e3b444c1e977d053 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Imidaprilat 40V, Positive-QTOF | splash10-0007-9410000000-08630f8b3a5958164079 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Imidaprilat 10V, Negative-QTOF | splash10-0059-0109000000-85019522c786c8c76d13 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Imidaprilat 20V, Negative-QTOF | splash10-0006-8539000000-b8655b8f422e331f5618 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Imidaprilat 40V, Negative-QTOF | splash10-0006-9500000000-cdf7c5bfaad296576300 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Imidaprilat 10V, Positive-QTOF | splash10-004i-0009000000-2346205b5410c69c549b | 2021-09-23 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Imidaprilat 20V, Positive-QTOF | splash10-03e9-1925000000-c0b2ed0519bf2dc40b71 | 2021-09-23 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Imidaprilat 40V, Positive-QTOF | splash10-016s-3900000000-c9e8c6e9815a4c714364 | 2021-09-23 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Imidaprilat 10V, Negative-QTOF | splash10-004i-0009000000-be90e2b489daf582f2f1 | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Imidaprilat 20V, Negative-QTOF | splash10-0059-2639000000-c8bc49157fba0a601caa | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Imidaprilat 40V, Negative-QTOF | splash10-0006-5900000000-8a33c559ab9193f1b173 | 2021-09-24 | Wishart Lab | View Spectrum |
NMR Spectra| Spectrum Type | Description | Deposition Date | Source | View |
|---|
| Predicted 1D NMR | 13C NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum |
|
|---|
| General References | - Yamanaka K, Morikawa S, Murata K, Banno K, Sato T, Takai T, Suzuki T, Mizobe M, Ito M, Ishibashi K: Radioimmunoassay for imidapril, a new angiotensin-converting enzyme inhibitor, and imidaprilat, its active metabolite, in human plasma and urine. J Pharm Biomed Anal. 1996 Jan;14(3):281-7. [PubMed:8851752 ]
- Hosoya K, Ishimitsu T: Protection of the cardiovascular system by imidapril, a versatile angiotensin-converting enzyme inhibitor. Cardiovasc Drug Rev. 2002 Summer;20(2):93-110. doi: 10.1111/j.1527-3466.2002.tb00185.x. [PubMed:12177688 ]
- Robinson DM, Curran MP, Lyseng-Williamson KA: Imidapril: a review of its use in essential hypertension, Type 1 diabetic nephropathy and chronic heart failure. Drugs. 2007;67(9):1359-78. doi: 10.2165/00003495-200767090-00008. [PubMed:17547476 ]
- Dolezal T: Imidapril in heart failure. J Renin Angiotensin Aldosterone Syst. 2006 Sep;7(3):146-54. doi: 10.3317/jraas.2006.024. [PubMed:17094051 ]
- Guo XG, Uzui H, Mizuguchi T, Ueda T, Chen JZ, Lee JD: Imidaprilat inhibits matrix metalloproteinase-2 activity in human cardiac fibroblasts induced by interleukin-1beta via NO-dependent pathway. Int J Cardiol. 2008 Jun 6;126(3):414-20. doi: 10.1016/j.ijcard.2007.08.134. Epub 2008 Jan 14. [PubMed:18192036 ]
|
|---|